TY - CHAP M1 - Book, Section TI - Essential Monoclonal Gammopathy A1 - Lichtman, Marshall A. A2 - Kaushansky, Kenneth A2 - Prchal, Josef T. A2 - Burns, Linda J. A2 - Lichtman, Marshall A. A2 - Levi, Marcel A2 - Linch, David C. PY - 2021 T2 - Williams Hematology, 10e AB - SUMMARYEssential monoclonal gammopathy is defined by two key features: (a) the presence of a monoclonal immunoglobulin (Ig) or a monoclonal Ig light chain in the serum and (b) the absence of evidence for an overt malignancy of B lymphocytes or plasma cells (eg, lymphoma, myeloma, or amyloidosis). The prevalence of essential monoclonal gammopathy depends on the demographic features in the population under study. In Americans of European descent, the prevalence increases from approximately 2% in individuals 50 years of age to approximately 7% in octogenarians. It is two to three times as prevalent in persons of African descent. The condition has been reported in association with a large variety of disorders, especially nonlymphocytic cancers. These coincidences are thought, in most cases, to be the chance concurrence of conditions that have a high prevalence in older persons. Some cases of essential monoclonal gammopathy are symptomatic because in these cases, the Ig can interact with plasma proteins, blood cells, kidney, ocular structures, or neural tissue and cause serious dysfunction, for example, an acquired bleeding disorder, renal insufficiency, or an incapacitating neuropathy. In such cases, disability may be so great that attempts to remove the Ig by plasmapheresis and to suppress its production using immune or cytotoxic therapy can be warranted. Because myeloma or lymphoma may emerge soon after the monoclonal Ig is first detected, subsequent evaluation of the patient is required to ascertain if essential monoclonal gammopathy is the appropriate diagnosis. Long-term follow-up at appropriate intervals is prudent to detect conversion from a stable, asymptomatic condition to a progressive lymphoma or myeloma, which occurs in approximately 0.75% of cases per year. In the absence of a symptomatic monoclonal gammopathy (eg, renal or neurologic involvement) or evolution to a progressive clonal gammopathy, periodic follow-up of patients is all that is required. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1178752222 ER -